JPRN-jRCTs051200076招募中3 期
The investigator-initiated international clinical trial on efficacy and safety of recombinant factor VIIa for hyperacute intracerebral hemorrhage - FASTEST
Toyoda Kazunori0 个研究点目标入组 400 人开始时间: 2020年11月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Patients aged 20 to 80 years with spontaneous intracerebral hemorrhage who can be treated within 120 minutes of stroke onset or last-known-well
排除标准
- •1) Score of 3 to 7 on the Glasgow Coma Scale
- •2) Secondary ICH related to known causes (e.g., trauma, aneurysm, arteriovenous malformation (AVM), oral anticoagulant use (vitamin K antagonists or novel oral anticoagulants) within the past 7 days, coagulopathy, etc.)
- •3) ICH volume < 2 cc and => 60 cc
- •4) Blood filling 2/3 or more of one lateral ventricle of the brain, OR, blood filling at least 1/3 of both lateral ventricles
- •5) Pre-existing disability (mRS > 2)
- •6) Symptomatic thrombo-embolic or vaso-occlusive disease in past 90 days (e.g., cerebral infarction, myocardial infarction, pulmonary embolus, deep vein thrombosis, or unstable angina)
- •7) Clinical or EKG evidence of ST elevation consistent with acute myocardial ischemia
- •8) Brainstem location of hemorrhage (patients with cerebellar hemorrhage may be enrolled)
- •9) Refusal to participate in study by patient, legal representative, or family member
- •10) Known or suspected thrombocytopenia (unless current platelet count documented above 50,000/micro L)
- •11) Unfractionated heparin use with abnormal PTT
- •12) Pro-coagulant drugs within 24 hours prior to patient enrollment into the FASTEST trial (example, tranexamic acid or aminocaproic acid)
- •13) Low-molecular weight heparin use within the previous 24 hours
- •14) Recent (within 90 days) carotid endarterectomy or coronary or cerebrovascular angioplasty or stenting
- •15) Advanced or terminal illness or any other condition the investigator feels would pose a significant hazard to the patient if rFVIIa were administered
- •16) Recent (within 30 days) participation in any investigational drug or device trial or earlier participation in any investigational drug or device trial for which the duration of effect is expected to persist until to the time of FASTEST enrollment
- •17) Planned withdrawal of care or comfort care measures
- •18) Patient known or suspected of not being able to comply with trial protocol (e.g., due to alcoholism, drug dependency, or psychological disorder)
- •19) Known or suspected allergy to trial medication(s), excipients, or related products
- •20) Contraindications to study medication
- •21) Previous participation in this trial (previously randomized)
- •22) Females of childbearing potential who are known to be pregnant or within 12 weeks post-partum and/or lactating at time of enrollment
研究者
相似试验
尚未招募
3 期
International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1Ewing SarcomaACTRN12624000532505niversity of Birmingham900
进行中（未招募）
3 期
International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1Ewing SarcomaCancerISRCTN17938906niversity of Birmingham900
招募中
3 期
An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma.10029211brain tumorEpendymomaNL-OMON54695Centre Leon Berard30
进行中（未招募）
1 期
An international clinical program for the diagnosis and treatment of children, adolescents and young adults with brain tumor.Histological diagnosis of intracranial localized ependymoma, including ependymoma variants: myxopapillary ependymoma, ependymoma (papillary, clear-cell, tanycytic), ependymoma RELA-fusion positive or anaplastic .MedDRA version: 20.0Level: PTClassification code 10014967Term: EpendymomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-002766-39-GRCentre Léon Bérard480
已完成
不适用
An investigator-initiated clinical research on the ability of an electroencephalogram analysis program to differentiate between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)JPRN-UMIN000035926Department of Behavioral Neurology and Neuropsychiatry, Osaka University United Graduate School of Child Development40